<DOC>
	<DOCNO>NCT02902978</DOCNO>
	<brief_summary>The primary purpose study evaluate safety , tolerability , pharmacokinetics single dose E6130 Japanese healthy adult male participant .</brief_summary>
	<brief_title>A Single Dose Study E6130 Japanese Healthy Adult Male Subjects</brief_title>
	<detailed_description>This study consist 8 cohort , Cohorts 1 8 . Cohorts 1 7 design single-center , single dose , placebo-controlled , randomize , ascend dose , double-blind study . Cohort 8 design single-center , single dose , randomize , open-label , two-group , two-period crossover study . Cohort 8 initiate Cohorts 1 7 complete .</detailed_description>
	<criteria>Inclusion Criteria 1 . Japanese healthy adult male age â‰¥20 &lt; 45 year time inform consent nonsmoker able stop smoking least 4 week study drug administration posttreatment examination . 2 . Has voluntarily consent , write , participate study . 3 . Has thoroughly brief condition participation study , willing able comply condition . Exclusion Criteria 1 . History surgical treatment may affect pharmacokinetics study drug screening . 2 . Suspected clinically abnormal symptom impairment organ function require treatment basis history complication screening , physical finding , vital sign , ECG finding , laboratory value screen baseline . 3 . History drug allergy screening . 4 . Judged investigator subinvestigator inappropriate participation study .</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>44 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>E6130</keyword>
	<keyword>Japanese healthy adult male participant</keyword>
	<keyword>Phase 1</keyword>
	<keyword>Pharmacokinetics</keyword>
</DOC>